The Department of Health and Human Services’ Biomedical Advanced Research and Development Authority will increase funding for its ongoing relationship with Cue Health, a healthcare technology firm based in San Diego, to develop an omicron-genotyping COVID-19 test. “An omicron-specific test will assist clinicians in providing patients better treatment options and containment strategies at the time of a positive diagnosis,” Cue CEO Ayub Khattak said in the press release. The test will complement the already existing Cue molecular COVID-19 test and will be compatible with the Cue Health Monitoring System and the Cue Health Mobile Application.

Source: Becker’s Hospitalreview